• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

泰国血友病的家庭治疗

Home therapy for hemophilia in Thailand.

作者信息

Isarangkura P, Chuansumrit A, Panthangkura W, Hathirat P, Pandhawong S

机构信息

Department of Pediatrics, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

出版信息

Southeast Asian J Trop Med Public Health. 1987 Dec;18(4):552-7.

PMID:3448780
Abstract

The home therapy for hemophilia in Thailand was initiated in 1979. The therapeutic material first used was frozen cryoprecipitate or fresh frozen plasma and later fresh dry plasma (FDP). During 1979-1982, ten patients attended regular home therapy. All of them lived in the rural area which were far from the provincial hospitals. The age ranged from 7 to 15 years with a mean age of 10 years. The duration of follow up ranged from 7 months to 7 years with a mean duration of 3 years. The utilized blood products as FDP varied from 3 to 30 bottles per year with a mean of 16 bottles per year or 0.5-2.9 bottles per kilogram body weight per year which increased gradually as the patients grow up. A total of 252 episodes of bleeding was recorded; mostly hemarthrosis 70% and muscular bleeding 19%. There was no any further disability detected in 6 cases (60%). The significant advantages were the reduction in admission rate from 6-8 admission per year to 0-1 admission per year; economic savings; psychological independence of well being and having a normal life. The disadvantage were inadequate dosage of infused material, delayed consultation and transfer which were preventable. Home therapy for hemophilia by using FDP is recommended for any developing country. It is safe, practical, efficient enough to preserve normal joint status and prevent disability.

摘要

泰国的血友病家庭治疗始于1979年。最初使用的治疗材料是冷冻冷沉淀或新鲜冷冻血浆,后来是新鲜干血浆(FDP)。1979年至1982年期间,10名患者接受了定期家庭治疗。他们都生活在远离省级医院的农村地区。年龄在7至15岁之间,平均年龄为10岁。随访时间从7个月到7年不等,平均为3年。每年使用的FDP血液制品从3瓶到30瓶不等,平均每年16瓶,即每年每公斤体重0.5至2.9瓶,随着患者长大而逐渐增加。共记录了252次出血事件;大部分是关节积血(70%)和肌肉出血(19%)。6例(60%)未发现进一步残疾。显著优点是住院率从每年6至8次降至每年0至1次;节省费用;心理上独立,感觉良好并能过上正常生活。缺点是输注材料剂量不足、咨询和转诊延迟,这些都是可以预防的。对于任何发展中国家,推荐使用FDP进行血友病家庭治疗。它安全、实用、足够有效,能够保持关节正常状态并预防残疾。

相似文献

1
Home therapy for hemophilia in Thailand.泰国血友病的家庭治疗
Southeast Asian J Trop Med Public Health. 1987 Dec;18(4):552-7.
2
Response of hemophilia A with bleeding to fresh dry plasma.患出血性甲型血友病对新鲜干燥血浆的反应。
Southeast Asian J Trop Med Public Health. 1993;24 Suppl 1:169-73.
3
National survey of patients with hemophilia and other congenital bleeding disorders in Thailand.泰国血友病及其他先天性出血性疾病患者的全国性调查。
Southeast Asian J Trop Med Public Health. 2004 Jun;35(2):445-9.
4
Haemophilia care in Zimbabwe.津巴布韦的血友病护理
Cent Afr J Med. 1996 May;42(5):153-6.
5
Lyophilized cryoprecipitate for children with hemophilia A.
J Med Assoc Thai. 2002 Jun;85 Suppl 1:S293-7.
6
HIV seroconversion in Thai hemophiliacs up to 1991.
Southeast Asian J Trop Med Public Health. 1993;24 Suppl 1:191-4.
7
Home treatment for patients with congenital bleeding disorders in a developing country.发展中国家先天性出血性疾病患者的家庭治疗
J Med Assoc Thai. 1999 Nov;82 Suppl 1:S57-62.
8
The safe blood components for a hemophilia patient: a case report.血友病患者安全血液成分:一例报告
Southeast Asian J Trop Med Public Health. 1993;24 Suppl 1:198-200.
9
Survival analysis of patients with haemophilia at the International Haemophilia Training Centre, Bangkok, Thailand.
Haemophilia. 2004 Sep;10(5):542-9. doi: 10.1111/j.1365-2516.2004.00928.x.
10
Exchange transfusion and pulse steroid therapy in a hemophiliac with inhibitor.1例血友病伴抑制剂患者的换血疗法和脉冲式类固醇治疗
J Med Assoc Thai. 1989 Jan;72 Suppl 1:139-43.

引用本文的文献

1
Care models in the management of haemophilia: a systematic review.血友病管理中的护理模式:一项系统综述
Haemophilia. 2016 Jul;22 Suppl 3(Suppl 3):31-40. doi: 10.1111/hae.13000.